Capstone Development Solutions specializes in developing pharmaceutical products on behalf of the world’s premier healthcare companies. It partners with corporations to lead pharmaceutical development and regulatory services for timely approval of products on their behalf. Water Street established Capstone in 2013 as a new way to support healthcare companies with maximizing their investment in developing pharmaceutical products and medical devices. Dan Robins, PhD, who has more than 20 years of research and development experience, leads the company’s team of scientists and regulatory experts. Al Heller, former CEO of American Pharmaceutical Partners (APPI), serves as chairman. Water Street is one of the few strategic investment firms to offer this unique solution to support companies with advancing their long-term goals for product development.

Dan Robins, Ph.D.


Work with us

Dan Robins has 20 years of pharmaceutical industry experience focused principally on research and development.  He is the former vice president of global development for Mylan, where he was responsible for injectable products.  His former business, Bioniche Pharma, where he led research and development in Ireland, was acquired by Mylan in 2010.  Prior to Bioniche Pharma, Dan was vice president of product development for Abraxis BioScience (formerly American Pharmaceutical Partners Inc.)  He also held leadership positions at Barr Laboratories, Inc. and scientific roles at Schering-Plough Research Institute, Mallinckrodt Veterinary and Pentech Pharmaceuticals.  Dan received master’s and doctorate degrees in chemistry from The Ohio State University and his master’s degree in business administration from New York University. He earned his bachelor’s degree from LaSalle University, where he serves as a trustee to the Board of Trustees.